The ESSENCE trial: Efficacy and safety of subcutaneous enoxaparin in unstable angina and non-Q-wave MI: A double-blind, randomized, parallel-group, multicenter study comparing enoxaparin and intravenous unfractionated heparin: Methods and design

Journal of Thrombosis and Thrombolysis

Volumn 4, Issue 2, 1997, Pages 271-274

  Cohen, Marc ^a   Blaber, Reginald ^a   Demers, Christine ^b   Gurfinkel, Enrique P ^c   Langer, Anatoly ^d   Fromell, Gregg ^e   Turpie, Alexander G G ^f   Premmereur, Jerome ^e  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b LAVAL UNIVERSITY   (Canada)

^c Instituto de Cardiologia y Cirugia Cardiovascular   (Argentina)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e SANOFI   (France)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Antithrombotic therapy; Clinical trials; Heparin; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT ELEVATION; SUBCUTANEOUS DRUG ADMINISTRATION; UNSTABLE ANGINA PECTORIS;

EID: 0030974967     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008803203290     Document Type: Article

References (19)

1. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992;305:913-920.
2. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 1992;340: 152-156.
3. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992;339:441-445.
4. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intra venous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-982.
5. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet. 1993;341:259-265.
6. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-1376.
7. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994;271:1780-1785.
8. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery - A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb. Haemost 1992;67:417-423.
9. Spiro TE, Johnson GJ, Christie MJ, et al. for the Enoxaparin Clinical Trial Group. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med 1994;121:81-89.
10. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334: 677-681.
11. Koopman MMW, Prandoni P, Piovella P, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687.
12. Wallentin L, for the Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
13. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-318.
14. Cohen M, Adams PC, Parry G, et al. and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in rest unstable angina and non-Q wave infarction in non-prior aspirin users. Primary end points analysis from the ATACS trial. Circulation 1993;89:81 88.
15. Wallentin L for the RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830.
16. Melandri G, Semprini F, Cervi V, Candiotti N, Branzi A, Palazzini E, Magnani B. Comparison of efficacy of low molecular weight heparin (Parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol 1993;72:450-454.
17. Edmondson, et al. Low-molecular weight heparin versus aspirin and dipyridamule after fernopopliteal bypass grafting. Lancet 1994;344:914-918.
18. Kay R, Wong KS, Yu YL, et al. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-1593.
19. Klein W for the FRIC Study Group. Low molecular weight heparin (dalteparin) in the management of unstable coronary artery disease (FRIC). (abstr) J Am Coll Cardiol 1996;359A.